Stibbe assists PanTera with the development of its Actinium Production Center
Stibbe’s projects practice assisted PanTera in relation to the development of its Actinium Production Center (APC), a pioneering facility dedicated to the large-scale production of Actinium-225 (Ac-225), a vital isotope used in targeted alpha therapy for cancer treatment.
PanTera, a joint venture between IBA and SCK CEN, aims to establish a reliable global supply of Ac-225 through a proprietary production process involving the irradiation of radium-226 with high-energy gamma beams. Earlier this year, PanTera obtained all necessary nuclear and environmental permits, enabling the start of construction of the APC.
The facility is scheduled to become operational in 2028, with commercial supply expected in 2029. Once fully operational, the APC will be capable of producing hundreds of curies of Ac-225 annually, positioning Belgium as a leader in nuclear medicine innovation and making a significant contribution to the global fight against cancer.
For further details, we refer to our client’s press release.
